Health Canada approves Dupixent™ as the first biologic for the treatment of adolescents with moderate-to-severe atopic dermatitis

Friday, September 27, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

____________________________

1

Dupixent™ (dupilumab) Product Monograph. September, 2019.

2

Dupixent™ (dupilumab) Product Monograph. September, 2019.

3

Dupixent™ (dupilumab) Product Monograph. September, 2019.

4

Dupixent™ (dupilumab) Product Monograph. September, 2019.

5

Mount Sinai. Patient Care Atopic Dermatitis. Available at: http://www.mountsinai.org/patient-care/health-library/diseases-and-conditions/atopic-dermatitis#risk. Accessed August 1, 2019.

6

Mount Sinai. Patient Care Atopic Dermatitis. Available at: http://www.mountsinai.org/patient-care/health-library/diseases-and-conditions/atopic-dermatitis#risk. Accessed August 1, 2019.

7

Eczema Society of Canada. (2017). Atopic Dermatitis Quality of Life Report (Moderate-to-Severe Disease – 2016/2017 Survey Results). Keswick, Ontario.

8

Dupixent™ (dupilumab) Product Monograph. September, 2019.

9

Dupixent™ (dupilumab) Product Monograph. September, 2019.

10

Dupixent™ (dupilumab) Product Monograph. September, 2019.

11

Dupixent™ (dupilumab) Product Monograph. September, 2019.

12

Dupixent™ (dupilumab) Product Monograph. September, 2019.

13

Dupixent™ (dupilumab) Product Monograph. September, 2019.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store